MagicBullet Therapeutics is an early clinical stage biotech company
focusing on new therapeutic modality of target protein degradation (TPD) and next generation kinase inhibitors to develop first-in-class targeted anticancer drugs that can be regulate life-threatening disease with unmet needs.
Our leadership team is comprised of experts in kinase and TPD developments, with extensive experience across leading drug discovery institutes and global pharmaceutical organizations.
Taken together, our research team has well-positioned in all key
disciplines required to make new innovative technologies happen to patients.